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Abstract
Background: Lipopolysaccharide (endotoxin, LPS) is a strong inducer of the innate immune response. It is widespread in
our environment, e.g. in house dust and contributes to asthma. Compared to humans, horses are even more sensitive to
LPS. However, data on LPS effects on the equine transcriptome are very limited. Using RNA-seq we analysed LPS-induced
differences in the gene expression in equine peripheral blood mononuclear cells at the gene and gene-network level in
two half-sib families and one group of unrelated horses.
Results: 24 h-LPS challenge of equine immune cells resulted in substantial changes in the transcriptomic profile
(1,265 differentially expressed genes) showing partial overlap with human data. One of the half-sib families showed a
specific response different from the other two groups of horses. We also identified co-expressed gene modules that
clearly differentiated 24 h-LPS- from non-stimulated samples. These modules consisted of 934 highly interconnected
genes and included genes involved in the immune response (e.g. IL6, CCL22, CXCL6, CXCL2), however, none of the top
ten hub genes of the modules have been annotated as responsive to LPS in gene ontology.
Conclusions: Using weighted gene co-expression network analysis we identified ten co-expressed gene modules
significantly regulated by in vitro stimulation with LPS. Apart from 47 genes (5%) all other genes highly interconnected
within the most up- and down-regulated modules were also significantly differentially expressed (FDR < 0.05). The LPS-
regulated module hub genes have not yet been described as having a role in the immune response to LPS (e.g. VAT1
and TTC25).
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Background
Innate immune response is the front line of the immune
defence and therefore plays a crucial role for the organ-
ism’s survival starting at the time of birth. The innate
immunity is non-specifically induced by invariant molecu-
lar structures present in pathogens, so called pathogen-
associated molecular patterns (PAMPs) [1]. The best
studied PAMP, lipopolysaccharide (LPS, also known as
endotoxin due to its content of a toxic lipid A), is a
component of the outer membrane of most gram-negative
bacteria [2, 3].
When LPS enters the blood stream, most commonly
through an intestinal lesion, it is opsonized by serum
LPS-binding protein [4], which is recognized by Toll-like
receptor 4 (TLR4) with the help of its co-receptor CD14
and another cell surface molecule, MD-2 [5, 6]. This rec-
ognition leads to a signalling cascade through MyD88-
and TRIF-dependent pathways [7], activating the NF-κB
transcription factor and finally inducing expression and
release of numerous cytokines, including TNF-α, IL-1,
IL-6, and IL-10 [8, 9]. This response and cascade are
evolutionarily well conserved and thus very similar
across species [10].
Sepsis is defined as a disrupted regulation of inflam-
mation in the face of bacterial or other microbial infec-
tion, which can ultimately lead to tissue damage, organ
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failure, and death. This response may consist of the
systemic inflammatory response (SIRS) or/and the com-
pensatory anti-inflammatory response (CARS), and the
balance between SIRS and CARS is crucial for the host
survival [11, 12]. SIRS often results from infections
caused by gram-negative bacteria [13, 14]. When sepsis
and SIRS lead to clinically evident cardiovascular com-
promise, the result is termed septic shock [15], which is
an uncontrolled life-threatening condition responsible
for a large proportion of deaths of hospitalized patients
worldwide [16]. Circulating LPS is believed to be the
principal trigger of the septic shock [6].
In contrast to the above-described systemic effects of
endotoxaemia (the presence of endotoxin in the blood),
inhaled LPS can induce airflow obstruction and neutro-
philic inflammation in healthy individuals. In asthmatic
patients the effect of LPS may be either beneficial or
harmful [17, 18], depending on the timing and dosage of
the LPS exposure, as well as other environmental and gen-
etic factors [17, 19–21]. In rats, early exposure to LPS,
prior to sensitization with an allergen, can attenuate in-
flammatory processes in lungs, eosinophilia, and bronchial
hypersensitivity, whereas endotoxin doses that are inhaled
later on (6 days after allergen exposure) increase airway
inflammation and edema [17, 22]. Low doses of LPS that
induce a ‘normal’ Th1 type response may be beneficial as
they are directing the Th1/Th2 balance towards Th1,
thereby reducing the effects of the allergy related Th2
type response. However, it has also been shown that
higher doses of LPS can contribute to occupational
asthma [23]. The positive modulatory and negative ex-
acerbating effects of LPS may be dependent on further
microbial antigens and genetic effects [19, 24–26]. For
instance, sequence variants in the TLR4 gene can affect
the responsiveness to LPS, and thereby influence the
prevalence of asthma in a population [17, 19].
The degree of LPS sensitivity seems to be species-
specific and horses are one of the most sensitive animals
in their response to LPS exposure, while rodents appear to
be much more resistant [11, 27, 28]. Endotoxaemia plays a
major role in many equine diseases, particularly in intes-
tinal disorders like acute colitis and ischemic bowel
diseases, which often present with colic as the principal
clinical manifestation [29]. Consequently, endotoxaemia is
one of the main causes of mortality and morbidity in
horses [30]. Horses suffering from colic have been shown
to have increased LPS plasma concentrations and fatal
colic cases had significantly higher LPS levels than non-
fatal colic cases [31].
In equine recurrent airway obstruction (RAO, ‘equine
asthma’), LPS does not cause the disease per se, which,
similar to the pathophysiology of asthma, is due to a
hypersensitivity to allergens in hay with a strong genetic
basis [32–37]. However, hay dust can also contain high
concentrations of LPS and inhaled endotoxin contributes
to airway inflammation in RAO [38–40]. Furthermore, it
is recognized that environmental exposure to microbial
compounds, that do not result in clinical disease, but act
through innate immune response mechanisms, influences
the development of adaptive immunity and consequently
allergy. Dendritic cells (DCs) are essential for priming T
helper-2 differentiation of naïve T cells towards aeroaller-
gens. However, contamination of antigens with PAMPs,
such as LPS, is required to activate DCs to mount an im-
mune response. Hammad et al. demonstrated in a mouse
model of asthma that TLR4 triggering of epithelial cells,
resulting in the release of innate pro-allergic cytokines, is
necessary to drive allergic inflammation via activation of
mucosal DCs [41]. To our knowledge equine global gene
expression changes after LPS stimulation have not yet
been analysed and reported. Genes function within net-
works that are typically redundant and regulatory mecha-
nisms frequently assure that up- or down-regulation of a
specific gene will be compensated by other genes [42]. It
has been shown that studying groups of co-expressed
genes, called gene modules, may better represent pathways
of genes, which are co-regulated and/or interact with each
other [43–47]. Weighted gene co-expression network ana-
lysis (WGCNA) is a tool that distinguishes modules of co-
expressed genes by correlation and clustering analysis. The
most highly connected genes within a module, ‘hub genes’,
can then serve as good biomarkers that are characteristic
for a phenotype studied, e.g. a disease.
Peripheral blood mononuclear cells (PBMCs) are a
mix of several immune cell types circulating in the
blood. They include cells that are involved in both the
innate (monocytes, dendritic cells) and the acquired
(lymphocytes) immune response systems. Therefore,
PBMCs to a certain extent reflect the immune system
status [48] and are widely used in systemic immune
response studies [49–55].
Gene expression changes upon LPS challenge of im-
mune cells have been intensively studied and well
characterized in many mammalian species, but data in
horses are limited despite the important impact of LPS
both in equine gastrointestinal and respiratory dis-
eases [29–31, 38–40]. Using a large RNA-seq dataset
generated in the context of previous studies [50, 56],
we report here the effect of 24 h in vitro LPS-stimulation
on the transcriptome of equine PBMCs and the effect of
genetic background on these LPS-induced transcriptomic
changes.
Methods
Ethics statement
All animal experiments were performed according to the
local regulations and with the consent of the horse owners.
This study was approved by the Animal Experimentation
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Committee of the Canton of Bern, Switzerland (BE33/07,
BE58/10 and BE10/13). The sample collection was previ-
ously described in detail in an earlier publication [49].
Samples, RNA extraction and RNA-seq
This study is based on the results generated in a previously
reported experiment and therefore all methods in detail are
described elsewhere [49, 50, 56]. Briefly, blood samples
were collected from 41 adult Warmblood horses (free of
RAO) from three cohorts: two half-sibling families (Fam1:
7 horses, Fam2: 9 horses) and a group of unrelated horses
(Un: 25 horses). About 8 million PBMCs from each horse
were stimulated with LPS or left unstimulated (mock) for
24 h and subsequently frozen at -80 °C until RNA was
extracted. High quality RNA (RIN > 8) was used for paired-
end library preparation and sequenced on an Illumina
HiSeq 2500 with 2 x 50 sequencing cycles. After quality
control the sequencing reads were mapped to the horse
reference genome (EquCab2). Raw data in binary-sequence
alignment format (BAM) are available from European
Nucleotide Archive (ENA) (http://www.ebi.ac.uk/ena/data/
view/PRJEB7497) and Short Read Archive (SRA) (http://
www.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?study=ERP007230).
Differential expression analysis
Reads with mapping quality ≥ 20 were counted gene-
wise with HTSeq [57] using the horse genome annota-
tion from Ensembl (version 72) and default parameters.
The differential expression analysis was performed with
edgeR R package (Additional file 1) [58]. From the
whole dataset used in our previous study [50, 56] we
used 41 control PBMC samples that were cultured
without any stimulating factor and 41 PBMC samples
from the same horses stimulated with LPS and applied
a filtering step in which we discarded all the genes with
less than 10 counts in more than 90% of samples. As an ini-
tial quality control step we performed principal component
analysis (PCA) using variance stabilized counts with indi-
vidual horse effect removed using the removeBatchEffect
function of limma R package (Additional file 1) [59, 60].
We next excluded outliers based on their Euclidean
distances and visual inspection of the sample dendrogram
(Fig. 1). Only horses with both mock and LPS stimulation
were kept for further analysis (39 horses, 78 samples,
Additional file 2).
For the model fitting, we applied a design that takes
into account the effects of stimulation and cohort with
interactions’ effects on the expression level:
gene expression
e
stimulationþ cohort þ cohort
: stimulation þ cohort : horse
The unrelated group of horses was set as the reference
group. The model was then fitted using the generalized
linear model implemented in edgeR [58]. The effect of
each factor on gene expression was tested and genes that
were differentially expressed with a significance level of
false discovery rate [61], FDR < 0.001 were assumed to
be differentially expressed genes (DEGs). The stringent
FDR threshold was set based on the large number of
DEGs identified, please see Results for details.
The DEGs identified were compared with two other
(microarray) studies available in public databases,
where human PBMCs were stimulated with LPS for
24 h: [62, 63]. Using the GEO2R tool [64] we retrieved
the DEGs between the control and 24 h-LPS stimulated
human PBMCs. While many probes in a microarray
can represent a single gene, we used only those genes,
for which all probes were consistently significantly
regulated by LPS with the same direction of regulation
(up or down). From our list of DEGs we used genes
with a gene symbol (genes without associated gene
names were filtered out for this comparison as no
human homologous gene could be identified). A strin-
gent significance threshold of FDR < 0.001 was applied
for enlisting the DEGs.
To get insight into the biological function of the
DEGs, they were subjected to enrichment analyses with
PANTHER overrepresentation test (release 20160715)
[65–67] using the gene ontology (GO) biological process
terms [68] and all 20,374 Equus caballus genes available
from the PANTHER database as the reference set. Only
the most specific GO subclasses from a group of all re-
lated parent classes in ontology were considered. The
PANTHER default Bonferroni corrected p-value (P-value)
significance threshold of 0.05 was used.
Co-expressed network analysis
Signed co-expression networks were built using the
WGCNA package in R [69] using variance stabilized counts
with individual horse effect removed (Additional file 1)
[59, 60]. BlockwiseModules function of the WGCNA
package, which allows for network construction from
the entire dataset, was used. For each set of genes a
pair-wise correlation matrix was computed across the
samples, and an adjacency matrix was calculated by
raising the correlation matrix to the power of 12 using
the scale-free topology criterion as suggested in [69].
Network interconnectedness (topological overlap meas-
ure) for each pair of the genes is calculated based on the
adjacency matrix. The resulting topological overlap matrix
is then converted to a dissimilarity measure and submitted
to hierarchical clustering. The clustering produces a
dendrogram, the branches of which represent similarly
expressed genes, with the most highly connected nodal
points or "hubs" located at the branch tips [69]. To cut the
branches (cluster individual branches in separate "mod-
ules”), we used the hybrid dynamic tree-cutting because it
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leads to robustly defined modules [69]. We set the mini-
mum module size to 40 genes and the minimum height
for merging modules to 0.25 (Additional file 1).
Each module was summarized by the first principal
component (i.e. eigengene) of the scaled (standardized)
module expression profiles. The module eigengene is a
single number that corresponds to the weighted average
expression of all module genes in a sample [69]. For
each module, the correlation between each gene expres-
sion values and module eigengene defines module mem-
bership (kME). The closer the absolute value of kME is
to 1, the stronger the evidence that the gene belongs to
the module represented by the module eigengene.
Significance of the LPS stimulation or cohort effect on
the gene module was calculated using expression values
of the module’s eigengene using limma package [60]
with the same linear model as the one used for gene-
wise differential expression analysis, without the horse
effect removed before (Additional file 1). The genes
initially assigned to the top two significant LPS-related
modules and with high module membership (kME ≥ 0.7)
were used for the enrichment analyses with PANTHER
overrepresentation test [65] as described for DEGs.
Results
Differential expression analysis
We used a subset of a previously published RNA-seq data-
set [50, 56]. Briefly, the 82 samples were derived from
three different cohorts of healthy Warmblood horses: one
group of horses that were unrelated at the parent level
and two half-sibling families. The PCA showed a clear
clustering of the samples according to the stimulation fac-
tor (Additional file 3). However, we removed three outliers
based on the sample dendrogram (Fig. 1) plus one add-
itional sample that matched the same horse as an outlier
removed in order to keep only the samples with both
mock and LPS stimulations required for the differential
expression analysis. We identified 1,265 out of 12,855 ana-
lysed genes to be differentially expressed genes (DEGs)
between LPS-stimulated and unstimulated samples in the
reference group of 24 unrelated horses (FDR < 0.001,
Additional file 4). The list of DEGs with associated gene
names available (n = 1,167, 92% of all DEGs) partially
overlapped DEGs from the other two studies on human
PBMCs stimulated with LPS [62, 63]: 287 genes from the
DEGs identified in this study were shared with at least one
of the two other studies and 44 were shared by all three
studies (Fig. 2). Log 2 fold changes (log2FC) of the DEGs
identified in equine PBMCs ranged from -6.77 (insulin-
like growth factor I, IGF1) to 4.81 (C-X-C motif chemo-
kine 6 precursor, CXCL6).
The PANTHER overrepresentation test [65] showed
that the DEGs identified are involved in many immune
response related processes (Fig. 3a). Ten most specific
GO subclasses with the highest fold enrichments (FEs)
are shown in Fig. 3a. The FE among the ten GO terms
ranged from 4.69 to 2.81 (P-value range: 2.80e-6 –
4.67e-2). The only significantly enriched PANTHER
Fig. 1 Sample hierarchical clustering. The samples clustered based on their Euclidean distance calculated with variance stabilized expression levels.
The red line indicates the threshold line that excludes outliers from further analysis and excluded samples are marked in red in the dendrogram
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pathway was the inflammation mediated by chemokine
and cytokine signalling pathway (P-value = 6.10e-3; FE =
2.22). Of the 1,265 DEGs 37 genes (3%) were not
matched to the PANTHER horse genome reference set
of genes.
Influence of the genetic background
We identified 16 genes (Additional file 4) that responded
differently to stimulation with LPS in family 1 and 155
in family 2 compared to the unrelated cohort (Additional
file 4, LPS:Fam1 and LPS:Fam2 effects). The LPS:Fam2
genes significantly enriched two GO biological processes:
the nucleic acid metabolic process (32 genes, P-value =
1.86e-2), and cellular macromolecule metabolic processes
(65 genes, P-value = 3.54e-6).
Co-expression analysis
Normalized read counts per gene for the 78 samples
grouped into two clusters accordingly to non- or LPS-
stimulated group (Fig. 1). WGCNA identified 30 mod-
ules of co-expressed genes that consisted of 53 to 1,542
genes (Additional file 5). Only 636 genes (5%) were not
included in any of the modules (by default WGCNA
groups such genes into a dummy “grey” module). Every
module was represented by its first principal component
called the module eigengene (see methods for details).
The association of eigengene expression with LPS stimu-
lation and cohort was investigated using the linear
model as explained in the Methods section. Of the 30
modules, ten were significantly associated with LPS
stimulation in the reference group of 24 unrelated
horses (FDR < 0.001), five modules were significant for
the LPS:Fam2 interaction effect (module eigengenes
responded differently to LPS stimulation in family 2
compared to unrelated cohort), and the most significant
LPS:Fam2 module was also significant for the LPS:Fam1
effect (Additional file 6).
The top significantly LPS-related modules (I and II)
clearly divided the samples into two separated clusters
of LPS-stimulated or unstimulated cells as shown in
Fig. 4. The barplots represent the expression of the
module eigengene and heatmaps the expression of the
module genes (kME ≥ 0.7) across the samples. The
genes with the strongest correlation (membership) with
the top two LPS-related modules’ eigengenes are listed
in Table 1.
The I and II module genes (with kME ≥ 0.7) were fur-
ther subjected to the enrichment analysis. We retrieved
all 12 significant GO biological processes with FE ≥ 2.81
(FE ≥ of the tenth most enriched biological process by
the LPS-induced DEGs). FE among the 12 GO terms
ranged from 12.74 to 3.11 (P-value range: 1.27e-5 –
3.1e-2). The processes were mostly related to the im-
mune response and included the response to LPS, as
well as a cell cycle related process (Fig. 3b). The most
enriched PANTHER GO-Slim biological process was the
negative regulation of apoptotic process (P-value =
4.72e-2), and none of the PANTHER pathway was sig-
nificantly enriched. Of the 934 module I and II genes 20
(2%) were not matched to the PANTHER horse genome
reference set of genes.
Discussion
LPS is known to be a strong inducer of the innate im-
mune response and changes in the gene expression can
be observed within one hour post LPS challenge [3, 70].
Actually, the majority of the studies on the LPS-induced
immune response focus on short-term effects. In con-
trast, this study investigated the consequences of a 24 h
LPS-challenge, which may better reflect continued ex-
posure to LPS, which is the cause of increased morbidity
and mortality in equine gastrointestinal [29–31] and re-
spiratory diseases [38–40]. As expected, in the equine
PBMCs studied here, 24 h LPS stimulation affected the
regulation of a substantial number of genes, almost 10%
of all genes studied at a FDR < 0.001. This fraction in-
creased to more than 24% of the studied genes when a
less stringent FDR threshold of < 0.05 was applied. The
magnitude of this effect was in accordance with previous
reports using genome-wide expression analyses demon-
strating that LPS strongly affects the transcriptomic pro-
file of blood cells revealed by in vitro and in vivo studies
in humans [62, 63, 71–74].
Fig. 2 Number of common and study-specific DEGs. The venn diagram
shows the overlap between the differentially expressed genes (DEGs)
identified in equine (Pacholewska et al.) and human (Smeekens at al,
Metcalf et al.) PBMCs stimulated with LPS for 24 h. From the equine gene
list only genes with orthologous human gene symbols were examined.
The number of replicates is denoted in the graph: LPS – samples
stimulated with LPS, CTL – unstimulated control samples
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While the horse is more sensitive to LPS than other
mammals that have been studied (including humans)
[27], the innate immune response to LPS is very similar
across species. This includes specific cell types and
mediators involved in the inflammatory cascade follow-
ing LPS challenge and is likely due to the fact that innate
immunity is a highly conserved, evolutionarily old im-
mune response [10].
Interestingly, our results from the differential expression
analysis agreed in part with similar studies on human
LPS-stimulated PBMCs [62, 63] (Fig. 2). Almost a quarter
of DEGs identified in our study overlapped DEGs from
both the studies on human PBMCs. It has to be also taken
into account that the overlap between the two human
studies was also surprisingly small: only 32% of DEGs
identified by Metcalf et al. was identified in the study of
Smeekens et al.; and only 15% vice versa. From a total of
239 common DEGs between the two studies on human
PBMCs, 18% were also identified in our study. While
these two studies focused on the defence against Candida
albicans and the age effect on innate response, they
employed the same duration of 24 h-LPS-stimulation as
in our study [62, 63]. Moreover, many of the equine LPS-
regulated genes (8%) did not have human homologs and
therefore had to be excluded from this comparison.
Although the immunological reaction to LPS has
already been described in several species, the response to
LPS is still poorly investigated in horses with only 41
unique equine proteins listed under the GO term
‘response to LPS’ (GO: 0032496, state of 23rd September
2016) with evidence based on computational analysis. Of
these 41 protein-coding genes 18 were also supported by
our study at FDR < 0.05 (CD40, CXCL2, CXCL6, CXCL8,
F2R, IL18, MIP-2BETA, PPBP, TLR4, TNFRSF11B, TNFR
SF18, TNFRSF1B, TNFRSF21, TNFRSF4, TNFRSF8,
ENSECAG00000012397, ENSECAG00000012560, ENSE-
CAG00000015037) and 11 when the stringent threshold
was applied (FDR < 0.001). The most up-regulated gene
in our dataset, the chemokine CXCL6, attracts neutro-
phils that are known to be involved in the first line of the
immune response [75, 76]. Among the up-regulated
DEGs, there were also genes previously identified as
LPS-induced genes in humans at the mRNA (using
reverse transcriptase quantitative PCR) or protein level
(e.g. IL1B, IL6, IL8 (also known as CXCL8), CCL22,
CXCL6) [75].
A
B
Fig. 3 Number of DEGs annotated in the gene ontology (GO) biological processes. Most enriched and significant (Bonferroni corrected p-value < 0.05)
biological processes annotated in the GO database and enriched by LPS-regulated genes identified in a) gene-wise and b) gene module-wise expres-
sion analysis (based on the GO database, release 2016-10-27 [65–67]). Each bar represents the number of genes enriched in the GO biological process.
Bars are sorted by the fold enrichment with the most enriched processes on top
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Previous genome-wide transcriptome profiling of
whole blood samples derived from paediatric patients
with SIRS, sepsis, or septic shock revealed putative use
of circulating IL27 in the blood as a biomarker for sepsis
in human patients [77, 78]. Interestingly, in our study
both genes encoding for the two subunits of IL27 (IL27
and EBI3) were up-regulated in LPS stimulated cells.
It is worth mentioning that sepsis is characterized by a
‘cytokine storm’ in the first phase, followed by a second
phase, after approximately 24 h, where the immune re-
sponse is ‘paralysed’ due to the apoptosis of activated
lymphocytes [79–81]. The suppression of the immune re-
sponse increases the risk of secondary infections in patients
with sepsis, which in turn represent a major cause of death
in these patients [82]. The apoptosis during immune par-
alysis in sepsis is believed to be induced by caspase signals,
namely death receptor induced caspase 8 (CASP8) or mito-
chondrial induced caspase 9 (CASP9) [83, 84]. Although we
did not identify significant changes in the expression levels
of CASP8 or CASP9, the most markedly down-regulated
gene by the LPS stimulation was the insulin-like growth
factor 1 gene (IGF1). IGF1 has been shown to have an anti-
apoptotic effect [85–88]. This decrease was in accordance
with another study in which LPS was shown to suppress
the expression of IGF1 in post mortem derived human
microglia on both mRNA and protein levels [89].
Because many genes’ functions are still unknown and
because genes often work within complex networks, we
hypothesized that the analyses of co-expressed groups of
genes could facilitate a deeper insight into LPS-induced
immune responses. Therefore, we assigned genes to
modules based on their co-expression. Ten out of 30
Fig. 4 The two most significantly LPS-associated gene modules across samples. Bar plots represent the expression level of the module eigengenes across
the samples. The light blue colour represents control mock-stimulated samples; the yellow colour represents samples stimulated with LPS. Heatmaps show
the expression levels of all the module gene members with kME≥ 0.7 (rows) across samples (columns). The expression values were scaled by rows and
denoted by colour from red (low) to green (high). Dendrograms of samples were produced using hierarchical cluster analysis
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modules identified possessed significant relationships
with LPS stimulation.
Interestingly, our analysis revealed that horse family 2 is
more distant from the unrelated group in their response
to LPS than family 1, based on both differential expression
and co-expression analysis (Additional files 4 and 6). We
noticed earlier that occurrence of equine asthma (RAO) is
correlated with an increased resistance against parasites
in unrelated Warmblood horses and in family 1, but
not in family 2 [49, 50, 90, 91]. Hub genes of the three
LPS:Fam2 specific modules that were not significant for
LPS:Fam1 may thus play a role in the response to
parasites.
As expected, some of the LPS-related modules identi-
fied in this study confirmed previous findings in regards
to our knowledge of LPS-induced immune responses,
but our analysis also revealed interesting novel aspects.
Genes of the two most strongly LPS-related modules
showed clear differences in the expression in stimulated
versus unstimulated PBMCs, as shown in Fig. 4. Among
the top significant LPS-related module genes there were
genes involved in immune response, including the re-
sponse to LPS (Fig. 3b). Indeed, the WGCNA analysis
revealed 272 genes from the two modules not identified
as LPS-regulated based on gene-wise differential expres-
sion analysis at FDR < 0.001. Only 47 of these were not
DEGs at the more permissive FDR threshold of 0.05.
Although module I included one of the hallmark-
genes of LPS-stimulation, IL6, the hub genes in this
module were BIRC3, encoding the baculoviral IAP
repeat containing 3, and VPS37A, encoding vacuolar
protein sorting 37 homolog A. BIRC3 was already im-
plicated in the pro-inflammatory cytokine induction
[92] and VPS37A in the inhibition of viral infection
[93]. The third hub gene was StAR related lipid transfer
domain containing 13 (STARD13), which is believed to
supress cell proliferation and motility [94] and there-
fore may be important for the regulation of the immune
response upon stimulation with LPS.
Even more interesting are hub genes from the LPS-
downregulated module: albeit the function of the vesicle
amine transport 1 protein encoded by VAT1 gene has
not been fully described, it has been shown that this
gene is expressed in human neutrophils and VAT1 pro-
tein is located peripherally in unstimulated neutrophils
with a more granular pattern upon stimulation with a
macrophage activator [95, 96]. Since our collection of
PBMCs did not contain neutrophils, the function of
VAT1 in PBMCs requires further investigation.
Surprisingly, we identified up- and down-regulated
genes involved in both positive and negative regulation
of apoptosis, e.g. the anti-apoptotic IGF1 gene, which
was the most down-regulated DEG in LPS-stimulated
samples. Apart from IGF1 module I hub genes included
guanidinoacetate N-gethyltransferase gene (GAMT) that
was also decreased in LPS-samples. This gene may have
also an anti-apoptotic role as it has been reported that
fibroblast cell lines from two GAMT-deficient patients
showed increased production of mitochondrial reactive
oxygen species and apoptotic rate [97]. As apoptosis in-
duces immunosuppression [98], the reduced expression
of the anti-apoptotic genes (IGF1, GAMT) may have a
role in the immune suppression phase of sepsis and sup-
port the concept of LPS induced immune regulation/
paralysis.
Another indication of the immune regulation by long-
term stimulation with LPS in our study was the down-
regulation of another hub gene, syndecan 3 (SDC3, module
I). SDC3 serves as a synovial binding site for IL-8 on endo-
thelial cells [99] thus down-regulation of SDC3 results in a
decrease in binding sites for the inflammatory IL8. The im-
mune regulation/paralysis could be further supported by
the down-regulation of the N-acylethanolamine acid ami-
dase (NAAA) and Fc fragment of IgG receptor and trans-
porter gene (FCGRT), module II hub genes. NAAA
degrades N-acylethanolamines in macrophages and is in-
volved in inflammatory processes [100] and has previously
Table 1 The genes with the strongest membership with the
top two LPS-related modules
Module Module hub genes Module
membership
LPS l
og2FC
DE FDR
module I BIRC3 0.97 1.26 1.89e-12
module I VPS37A 0.95 0.53 3.97e-9
module I STARD13 0.94 0.80 1.01e-4
module I SOD2 0.94 1.75 8.83e-16
module I SLC1A2 0.94 2.83 3.62e-18
module I ARHGEF3 0.94 0.53 3.39e-8
module I TTC25 0.94 0.84 5.30e-8
module I SLC39A14 0.93 1.80 2.80e-12
module I ENSECAG00000002023,
superoxide dismutase
0.93 1.79 5.69e-16
module I TREX1 0.93 0.85 2.25e-7
module II VAT1 0.95 −1.13 1.68e-16
module II SDC3 0.94 −2.27 1.16e-9
module II FCGRT 0.94 −1.39 1.42e-10
module II SLC46A1 0.94 −1.80 8.21e-18
module II NAAA 0.94 −0.94 2.53e-20
module II CSF1R 0.93 −1.54 1.43e-11
module II MAN2B1 0.93 −0.44 5.77e-10
module II ARRB1 0.92 −1.03 3.19e-9
module II GAMT 0.92 −2.40 3.77e-19
module II S100A4 0.92 −1.10 4.29e-12
For every module the ten most correlated genes are listed with the following
features: module membership, log2 fold change of the expression regulated
by LPS, false discovery rate for the gene-wise differential expression (DE)
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been reported as potential anti-inflammatory agent
[101–104]. FCGRT protects immunoglobulin G from
degradation, thus its expression reduced may be the result
of the immune response regulatory mechanisms [105].
What is noteworthy is that none of the 20 hub genes
of the I and II modules listed in Table 1 has been anno-
tated in the GO term response to lipopolysaccharides
(GO:0032496). Among these hub genes was also the tet-
ratricopeptide repeat domain 25 gene (TTC25) that has
been poorly characterized so far. Nonetheless, this gene
seems to play an important biological role in the respira-
tory tract and other organ systems that depend on intact
ciliary function, as it has been recently reported that
mutations in the TTC25 lead to primary ciliary dyskin-
esia [106]. However, we also need to caution that this
study was performed on RNA-seq data only and individ-
ual gene specific function and their role in LPS-related
pathways would still require further functional analysis.
Conclusions
The WGCNA revealed novel aspects in an already much
studied field, such as the response to LPS. We identified
two co-expressed gene modules that clearly separated
LPS- from non-stimulated cells. Apart from known LPS-
response genes (e.g. IL6, IL8, CXCL6) the two modules
identified comprised novel genes with potential roles in
LPS-response pathways (e.g. VAT1 and TTC25). More-
over, the regulation of genes involved in the apoptotic
process in our data suggests that 24 h stimulation with
LPS may reflect the ‘immune paralysis’ phase observed
in patients with bacterial sepsis. In addition, we further
confirmed that the family 2 horses differ in their im-
mune response from family 1 and unrelated horses.
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